Supplemental material for Impact of first-line infliximab on the pharmacokinetics of second-line vedolizumab in inflammatory bowel diseases

Supplemental Material for Impact of first-line infliximab on the pharmacokinetics of second-line vedolizumab in inflammatory bowel diseases by Claire Liefferinckx, Bram Verstockt, Ann Gils, Sophie Tops, Wouter Van Moerkercke, Severine Vermeire and Denis Franchimont in United European Gastroenterology Journal